Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses LNA Technology to Becton Dickinson

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has granted a non-exclusive license for its locked nucleic acids technology to Becton Dickinson for the development of diagnostics for infectious diseases.

Under the terms of the deal, Exiqon will receive upfront and milestone payments and royalties on global sales of products stemming from the agreement. No other financial terms were disclosed.

BD will market a number of defined LNA-enhanced products to run on its BD Max next-generation system for molecular diagnostics based on real-time PCR. The agreement is the first time that the LNA technology is being applied in the development of diagnostic products with the goal of gaining clearance from the US Food and Drug Administration, Exiqon said in a statement.

Exiqon plans to license out its LNA technology in markets that it does not plan to pursue itself, it added.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.